Research programme: SNA based therapeutics - Exicure

Drug Profile

Research programme: SNA based therapeutics - Exicure

Alternative Names: AST 008; SNA constructs - Exicure; SNA targeting IL17RA - Exicure; SNA targeting IL4RA - Exicure; Spherical nucleic acid constructs - Exicure

Latest Information Update: 14 Jan 2017

Price : $50

At a glance

  • Originator AuraSense Therapeutics
  • Developer Exicure
  • Class Nucleic acids
  • Mechanism of Action Gene modulators; Immunomodulators; Immunosuppressants; Interleukin 1 beta modulators; Interleukin 4 receptor modulators; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Brain cancer; Cancer; Fibrosis; Inflammation; Lymphoma; Skin disorders; Solid tumours; Transplant rejection
  • Research Atopic dermatitis; Epidermolysis bullosa; Eye disorders; Gastrointestinal disorders; Respiration disorders

Most Recent Events

  • 11 Jan 2017 Early research in Atopic dermatitis, Epidermolysis bullosa, Eye disorders, Gastrointestinal disorders in USA (unspecified route) (Exicure pipeline, January 2017)
  • 11 Jan 2017 Preclinical trials in Psoriasis in USA (Topical) (Exicure pipeline, January 2017)
  • 29 Aug 2016 Preclinical trials in Inflammation in USA (Exicure pipeline, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top